|
Sign In to gain access to subscriptions and/or personal tools.
|
Toxicologic Pathology, Vol. 27, No. 5,
536-544 (1999)
DOI: 10.1177/019262339902700507
Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal Administration
Joyce Mordenti
Department of Experimental Therapeutics Genentech, Inc.
R. Andrew Cuthbertson
Department of Cardiovascular Research, Genentech, Inc., South San Francisco, California 94080
Napoleone Ferrara
Department of Cardiovascular Research, Genentech, Inc., South San Francisco, California 94080
Karen Thomsen
Department of Experimental Therapeutics Genentech, Inc.
Lea Berleau
Department of Experimental Therapeutics Genentech, Inc.
Vojtech Licko
Department of Experimental Therapeutics Genentech, Inc.
Philip C. Allen
California Regional Primate Research Center, University of California-Davis, Davis, California 95616
Celia R. Valverde
California Regional Primate Research Center, University of California-Davis, Davis, California 95616
Y. Gloria Meng
Department of Bioanalytical Technology, Genentech, Inc.
David T.W. Fei
Department of Bioanalytical Technology, Genentech, Inc.
Kathleen M. Fourre
Department of Assay Services, Genentech, Inc.
Anne M. Ryan
Department of Pathology, Genentech, Inc.
Access of recombinant proteins to the retina following intravitreal administration is poorly understood. A study was conducted in male Rhesus monkeys (15 to 28 mo of age; 2.8-3.3 kg) in order to compare the intraocular tissue distribution, pharmacokinetics, and safety of 125Iodine (I)-labeled full-length humanized rhuMAb HER2 antibody (148 kD) and of 125I-labeled humanized rhuMAb vascular endothelial growth factor Fab antibody (48.3 kD) following bilateral bolus intravitreal injection on day 0 (5 animals/group). The dose administered to each eye was 25 µg (9-10 µCi) in 50 µl. Animals were euthanatized on day 0 (1 hr postdose) and on days 1, 4, 7, and 14. Safety assessment included direct ophthalmoscopy, intraocular pressure measurements, clinical observations, body weight, and hematology and clinical chemistry panels. Blood and vitreous samples were collected daily (blood only) and at necropsy for pharmacokinetics and analysis for antibodies to the test materials; the ocular tissue distribution of the test material was evaluated by microautoradiography. All animals completed the study. Microautoradiography demonstrated that the full-length antibody did not penetrate the inner limiting membrane of the retina at any of the time points examined. In contrast, the Fab antibody fragment diffused through the neural retina to the retinal pigment epithelial layer at the 1-hr time point and persisted in this location for up to 7 days. Systemic exposure to test material was low but variable: the highest plasma concentration of the full-length antibody was 20.3 ng/ml, whereas plasma concentrations for the Fab antibody remained below the limit of quantitation (i.e., <7.8 ng/ml). An immune response to the test material was not evident in either treatment group. The half-life in vitreous was 5.6 days for the full-length antibody and 3.2 days for the Fab antibody. The shorter intravitreal half-life of the Fab antibody is related to its smaller size and its significant diffusion through the retinal layers. The differences in pharmacokinetics and tissue distribution that are noted between the full-length and Fab antibodies in this study identify potential therapeutic approaches that may be exploited in specific disease conditions.
Key Words: Recombinant protein • monoclonal antibody • retinal drug delivery • pharmacokinetics • microautoradiography • intravitreal • intraocular • immunogenicity
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. J. Hernandez-Pastor, A. Ortega, A. Garcia-Layana, and J. Giraldez
Ranibizumab for neovascular age-related macular degeneration
Am. J. Health Syst. Pharm.,
October 1, 2008;
65(19):
1805 - 1814.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M W Stewart and P J Rosenfeld
Predicted biological activity of intravitreal VEGF Trap
Br. J. Ophthalmol.,
May 1, 2008;
92(5):
667 - 668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Peters, P Heiduschka, S Julien, K-U Bartz-Schmidt, and U Schraermeyer
Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye
Br. J. Ophthalmol.,
April 1, 2008;
92(4):
541 - 544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Dib, M. Maia, I. M. Longo-Maugeri, M. C. Martins, J. S. Mussalem, C. C. Squaiella, F. M. Penha, O. Magalhaes Jr, E. B. Rodrigues, and M. E. Farah
Subretinal Bevacizumab Detection after Intravitreous Injection in Rabbits
Invest. Ophthalmol. Vis. Sci.,
March 1, 2008;
49(3):
1097 - 1100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F Gomi, M Sawa, H Sakaguchi, M Tsujikawa, Y Oshima, M Kamei, and Y Tano
Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy
Br. J. Ophthalmol.,
January 1, 2008;
92(1):
70 - 73.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. F. Bashshur, A. Schakal, R. N. Hamam, C. P. El Haibi, R. F. Jaafar, and B. N. Noureddin
Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration
Arch Ophthalmol,
October 1, 2007;
125(10):
1357 - 1361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Heiduschka, H. Fietz, S. Hofmeister, S. Schultheiss, A. F. Mack, S. Peters, F. Ziemssen, B. Niggemann, S. Julien, K. U. Bartz-Schmidt, et al.
Penetration of Bevacizumab through the Retina after Intravitreal Injection in the Monkey
Invest. Ophthalmol. Vis. Sci.,
June 1, 2007;
48(6):
2814 - 2823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H Sakaguchi, Y Ikuno, F Gomi, M Kamei, M Sawa, M Tsujikawa, Y Oshima, S Kusaka, and Y Tano
Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia
Br. J. Ophthalmol.,
February 1, 2007;
91(2):
161 - 165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. R. Imrie and C. Bailey
New treatments for age-related macular degeneration
Age Ageing,
January 1, 2007;
36(1):
8 - 10.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Stone
A Very Effective Treatment for Neovascular Macular Degeneration
N. Engl. J. Med.,
October 5, 2006;
355(14):
1493 - 1495.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Costa, R. Jorge, D. Calucci, J. A. Cardillo, L. A. S. Melo Jr, and I. U. Scott
Intravitreal Bevacizumab for Choroidal Neovascularization Caused by AMD (IBeNA Study): Results of a Phase 1 Dose-Escalation Study.
Invest. Ophthalmol. Vis. Sci.,
October 1, 2006;
47(10):
4569 - 4578.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Gillies
What We Don't Know About Avastin Might Hurt Us
Arch Ophthalmol,
October 1, 2006;
124(10):
1478 - 1479.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D Wong and G Kyle
Some ethical considerations for the "off-label" use of drugs such as Avastin.
Br. J. Ophthalmol.,
October 1, 2006;
90(10):
1218 - 1219.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M S Spitzer, B Wallenfels-Thilo, A Sierra, E Yoeruek, S Peters, S Henke-Fahle, K U Bartz-Schmidt, P Szurman, and on behalf of the Tuebingen Bevacizumab Study Group
Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells
Br. J. Ophthalmol.,
October 1, 2006;
90(10):
1316 - 1321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. van Wijngaarden, D. J. Coster, and K. A. Williams
Inhibitors of Ocular Neovascularization: Promises and Potential Problems
JAMA,
March 23, 2005;
293(12):
1509 - 1513.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Gaudreault, D. Fei, J. Rusit, P. Suboc, and V. Shiu
Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration
Invest. Ophthalmol. Vis. Sci.,
February 1, 2005;
46(2):
726 - 733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L. Jackson, J. Hillenkamp, T. H. Williamson, K. W. Clarke, A. I. Almubarak, and J. Marshall
An Experimental Model of Rhegmatogenous Retinal Detachment: Surgical Results and Glial Cell Response
Invest. Ophthalmol. Vis. Sci.,
September 1, 2003;
44(9):
4026 - 4034.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L. Jackson, R. J. Antcliff, J. Hillenkamp, and J. Marshall
Human Retinal Molecular Weight Exclusion Limit and Estimate of Species Variation
Invest. Ophthalmol. Vis. Sci.,
May 1, 2003;
44(5):
2141 - 2146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Krzystolik, M. A. Afshari, A. P. Adamis, J. Gaudreault, E. S. Gragoudas, N. A. Michaud, W. Li, E. Connolly, C. A. O'Neill, and J. W. Miller
Prevention of Experimental Choroidal Neovascularization With Intravitreal Anti-Vascular Endothelial Growth Factor Antibody Fragment
Arch Ophthalmol,
March 1, 2002;
120(3):
338 - 346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Burkhardt, A. M. Ryan, and P.-G. Germann
Practical Aspects of Discovery Pathology
Toxicol Pathol,
January 1, 2002;
30(1):
8 - 10.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H.-P. Gerber, J. Kowalski, D. Sherman, D. A. Eberhard, and N. Ferrara
Complete Inhibition of Rhabdomyosarcoma Xenograft Growth and Neovascularization Requires Blockade of Both Tumor and Host Vascular Endothelial Growth
Cancer Res.,
November 1, 2000;
60(22):
6253 - 6258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
